Project Description

Eye oitnment Nucleavir

Unguentum Nucleavir  ophtalmicum

international nonproprietary name

Not established

Ref

BP-0092

Pharmacotherapeutic group

Medication for eye treatment. Antiviral agent

Composition of the preparation

Agent: 1 g of ointment contains 0,03 g of cyclocitidinehydrophosphate

Auxiliaries: clinical liquid paraffin, white petrolatum

Pharmacological action

Pharmacodynamics

The agent of eye ointment Nucleavir is cyclocitidinehydrophosphate, synthetic analogue of purine nucleoside that is active to the human herpes viruses, including Herpes simplex of types 1 and 2, virus Varicella Zoster. The medication is effective in case of the pathogen resistance to acyclovir and phosphonoacetic acid. It has a direct virus-inhibitory action providing a complete blockade of the virus in the pathologic nidus.

The medication provides a rapid arresting of inflammation and improvement of the visual organ functions: reduction in number of infiltrations in the cornea, acceleration of ulceration epithelization and oxyopia have been clinically proved. The eye ointment Nucleavir reduces ophtalmalgia, lacrimation, conjunctiva reddening, eyelid oedema. It reduces the possibility of dissemination and prevents the formation of new niduses, as well as reduces the risk of development of severe complications of herpetic eye infection.

The medication is effective in mono- or combined therapy of superficial or deep types of herpetic eye lesion.

Pharmacokinetics

On using the eye ointment Nucleavir the agent (cyclocitidinehydrophosphate) practically does not get into the systemic blood flow. The therapy concentration in eye tissues is achieved on single application.

Indications 

The medication is used in adults for local treatment of herpetic eye diseases: herpetic keratitis, herpetic keratoconjunctivitis, herpetic keratouveitis, keratoiridocyclitis (with or without ulceration).

special indication

Treatment shall be started on the first symptoms of the disease.

Side effects

As a rule, negative effects of the medication use have not been registered.

In rare cases burning, itching, temporal conjunctiva reddening, eyelid eodema are possible that disappear after the treatment termination.

Contraindications

High individual sensitivity to the medication, pregnancy, lactation.

Clinical data on application of eye ointment Nucleavir in children are not available.

special warning

Not established

Dosage and method of administration

The medication is to be put into the conjuctival cavity 3 — 5 times a day in case of superficial herpetic infection, 4-5 times – in case of deep infection. Single dose of eye ointment Nucleavir is a column 10 mm high.

The treatment is to be continued till disappearance of local symptoms. The duration of treatment for superficial herpetic infection is about 7-14 days (till disappearance of local symptoms), for deep forms — 14-21 days.

overdosage

Cases of overdosing on using the eye ointment Nucleavir have not been specified.

safety measures

Special precautions for application of eye ointment Nucleavir are not indicated.

Side effects

As a rule, negative effects of the medication use have not been registered.

In rare cases burning, itching, temporal conjunctiva reddening, eyelid eodema are possible that disappear after the treatment termination.

Contraindications

High individual sensitivity to the medication, pregnancy, lactation.

Clinical data on application of eye ointment Nucleavir in children are not available.

Interactions with other medicinal preparations

No negative effects on Nucleavir application with other medications have been specified.

The medication can be used for treatment of ophthalmoherpes in the complex with instillation of human leukocyte interferon, mydriatics, sulphanamides, antibacterial preparations.

The form of release

Oitment 5% in tubes 5 g or 3 g each.